Comparative Pharmacology
Head-to-head clinical analysis: A HYDROCORT versus ADVAIR HFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A HYDROCORT versus ADVAIR HFA.
A-HYDROCORT vs ADVAIR HFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone is a corticosteroid hormone that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, inhibit immune response, and regulate metabolism.
ADVAIR HFA is a combination of fluticasone propionate, a corticosteroid that reduces inflammation by inhibiting multiple inflammatory cell types and mediators, and salmeterol, a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing cAMP levels.
Adrenal insufficiency: oral 20-30 mg/day in divided doses; inflammatory conditions: 5-60 mg/day oral; IV/IM: hydrocortisone sodium succinate 50-100 mg every 4-6 hours.
2 inhalations (fluticasone 230 mcg/salmeterol 21 mcg per inhalation) twice daily, approximately 12 hours apart, via oral inhalation. Maximum: 2 inhalations twice daily.
None Documented
None Documented
Terminal half-life: 1.5-2 hours (cortisol); clinical effect persists 8-12 hours due to glucocorticoid receptor binding
Fluticasone propionate: 7.8 hours (inhalation), prolonged in hepatic impairment. Salmeterol: 5.5 hours.
Renal (primarily as metabolites, <1% unchanged); biliary/fecal (<5%)
Fluticasone propionate: Renal <5%, fecal (primarily as metabolites) ~90%. Salmeterol: Renal 25% (as metabolites), fecal 60%.
Category C
Category C
Corticosteroid
Corticosteroid/LABA Combination